Stock CTMX CYTOMX THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-08 pm EDT 		Pre-market 07:59:35 pm
4.19 USD +2.95% Intraday chart for CytomX Therapeutics, Inc. 2.74 -34.61%
May. 08 Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M MT
May. 07 CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab) CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CytomX Therapeutics : First Quarter Earnings Update - May 8, 2024
PU
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M
MT
CytomX Therapeutics: Q1 Earnings Snapshot
AQ
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
AQ
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
AQ
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)
CI
Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8
MT
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
AQ
JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight
MT
CytomX Therapeutics : 2023 Annual Report
PU
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
AQ
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors
CI
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
AQ
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
AQ
CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors
CI
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
AQ
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas
CI
Transcript : CytomX Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM
BMO Capital Adjusts CytomX Therapeutics Price Target to $3.25 From $3.30, Maintains Market Perform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTMX Stock
  4. News CytomX Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW